Endoscopic resection of residual rectal neoplasia after definitive chemoradiotherapy for rectal cancer

IF 3.2 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY
Robert Klimkowski , Jakub Krzyzkowiak , Nastazja Dagny Pilonis , Krzysztof Bujko , Michal F. Kaminski
{"title":"Endoscopic resection of residual rectal neoplasia after definitive chemoradiotherapy for rectal cancer","authors":"Robert Klimkowski ,&nbsp;Jakub Krzyzkowiak ,&nbsp;Nastazja Dagny Pilonis ,&nbsp;Krzysztof Bujko ,&nbsp;Michal F. Kaminski","doi":"10.1016/j.bpg.2024.101896","DOIUrl":null,"url":null,"abstract":"<div><p>The conventional approach to treating locally advanced rectal cancer, commonly defined as cT3 or cT4 primary tumors or with nodal metastases, involves chemoradiation (CRT) followed by surgical resection. There is a growing recognition of the potential for nonsurgical management following CRT or total neoadjuvant therapy (TNT), which allows for organ preservation. “Watch and wait” strategy may be considered if complete clinical response is achieved. In cases when adenoma or superficial cancer is present, a novel approach known as “salvage endoscopic resection of the residual disease” is emerging as a viable nonsurgical option for carefully selected patients. This review discusses available evidence and future potential for endoscopic management of residual neoplasia after oncological treatment of rectal cancer.</p></div>","PeriodicalId":56031,"journal":{"name":"Best Practice & Research Clinical Gastroenterology","volume":"68 ","pages":"Article 101896"},"PeriodicalIF":3.2000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Best Practice & Research Clinical Gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1521691824000155","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The conventional approach to treating locally advanced rectal cancer, commonly defined as cT3 or cT4 primary tumors or with nodal metastases, involves chemoradiation (CRT) followed by surgical resection. There is a growing recognition of the potential for nonsurgical management following CRT or total neoadjuvant therapy (TNT), which allows for organ preservation. “Watch and wait” strategy may be considered if complete clinical response is achieved. In cases when adenoma or superficial cancer is present, a novel approach known as “salvage endoscopic resection of the residual disease” is emerging as a viable nonsurgical option for carefully selected patients. This review discusses available evidence and future potential for endoscopic management of residual neoplasia after oncological treatment of rectal cancer.

直肠癌明确化放疗后的直肠残余肿瘤内窥镜切除术
治疗局部晚期直肠癌(通常定义为 cT3 或 cT4 原发肿瘤或有结节转移)的传统方法包括化疗(CRT)和手术切除。越来越多的人认识到,CRT 或新辅助治疗(TNT)后的非手术治疗具有保留器官的潜力。如果取得了完全的临床反应,可以考虑 "观察和等待 "策略。对于存在腺瘤或浅表癌的病例,一种被称为 "残余疾病抢救性内镜切除术 "的新方法正逐渐成为经过严格筛选的患者的可行非手术疗法。本综述将讨论直肠癌肿瘤治疗后残余肿瘤的内镜治疗的现有证据和未来潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.50
自引率
0.00%
发文量
23
审稿时长
69 days
期刊介绍: Each topic-based issue of Best Practice & Research Clinical Gastroenterology will provide a comprehensive review of current clinical practice and thinking within the specialty of gastroenterology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信